Abhinav Gupta, MD
Pulmonary Disease · Columbia, SCNPI 1346290780
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.0%), food and beverage and grants — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by United Therapeutics Corporation at 54.1% of the total. Reporting peaked in 2023 at $2,289 and has fallen 86.2% since, to $315 in 2025.
Across 29 payments — averaging $137.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$2K
- Genentech, Inc.$1K
- Medtronic$207
- Pulmonx Corporation$143
- Boehringer Ingelheim$121
- AstraZeneca$121
- plus $246 from 7 others
Across 104 payments — averaging $2960.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$308K
What the payments were for
- Grants$1,00025%
- Travel & lodging$1,72143%
- Food & beverage$1,20030%
- Education$802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 13 | $2,163 |
| Genentech, Inc. | 1 | $1,000 |
| Medtronic | 3 | $207 |
| Pulmonx Corporation | 1 | $143 |
| Boehringer Ingelheim | 1 | $121 |
| AstraZeneca | 1 | $121 |
| Regeneron Healthcare Solutions, Inc. | 2 | $120 |
| Bard Peripheral Vascular, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Resmed Corp | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,001 in reported general payments places this provider in the 55th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 89 | $1,170,332 |
| Pirfenidone | 59 | $220,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 184 | $138,904 |
| TezspireTezepelumab-Ekko | 26 | $108,208 |
| Fasenra PenBenralizumab | 16 | $95,409 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $76,439 |
| Spiriva RespimatTiotropium Bromide | 66 | $41,850 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $37,686 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $23,641 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $13,378 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $11,398 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $10,090 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $8,277 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 250 | $8,116 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $8,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $121 | $1,222,272178 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $121 | $196,045171 claims |
| MerckDulera | $19 | $4,19813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Columbia
- Richard BoganColumbia$1.1M
- Laura HerpelColumbia$254K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
- Karla Cruz MorelColumbia$74K
- Gregory FeldmanColumbia$73K
- Carlton CauthenColumbia$17K
- Liang ZhaColumbia$10K
- Todd GandyColumbia$10K
- Matthew VarnerColumbia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.